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Abstract: Breast cancer is a heterogeneous disease with a complex etiology that develops from different cellular lineages, 
progresses along multiple molecular pathways, and demonstrates wide variability in response to treatment. The “standard 
of care” approach to breast cancer treatment in which all patients receive similar interventions is rapidly being replaced by 
personalized medicine, based on molecular characteristics of individual patients. Both inherited and somatic genomic 
variation is providing useful information for customizing treatment regimens for breast cancer to maximize efficacy and 
minimize adverse side effects. In this article, we review (1) hereditary breast cancer and current use of inherited suscepti-
bility genes in patient management; (2) the potential of newly-identified breast cancer-susceptibility variants for improv-
ing risk assessment; (3) advantages and disadvantages of direct-to-consumer testing; (4) molecular characterization of 
sporadic breast cancer through immunohistochemistry and gene expression profiling and opportunities for personalized 
prognostics; and (5) pharmacogenomic influences on the effectiveness of current breast cancer treatments. Molecular 
genomics has the potential to revolutionize clinical practice and improve the lives of women with breast cancer.  
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INTRODUCTION 
  Breast cancer is the most frequently occurring cancer and 
the leading cause of death in women between 20 and 59 
years of age in the United States [1]. Over the last fifty years, 
the incidence of breast cancer has increased dramatically, 
such that today one in eight women are expected to develop 
breast cancer during her lifetime. Last year in the United 
States, more than 40,000 women died from breast cancer [2] 
and the cost of treatment for breast cancer patients exceeded 
$8 billion [3].  
  Breast cancer has a complex etiology where susceptibil-
ity is influenced by both environmental and genetic factors. 
Considerable experimental and epidemiological evidence 
suggests that lifetime exposure to endogenous hormones, 
notably estrogens and androgens, promotes breast carcino-
genesis. In population-based studies, factors related to in-
creased estrogen exposure throughout a woman’s lifetime, 
such as early menarche, late menopause, use of oral contra-
ceptives, and hormone replacement therapy, have been asso-
ciated with a ~2-fold increase in breast cancer risk among 
premenopausal women [4-6]. Other risk factors including 
age, family history, late age (>30 years) at first pregnancy or 
never being pregnant, and high breast density [7], as well as 
modifiable risk factors such as nutrition [8], exercise, and 
alcohol/tobacco use are also important in defining risk for 
breast cancer.  
  Heterogeneity in clinical, pathological, and molecular 
characteristics makes breast cancer a challenging disease to  
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manage. Pathological characterization of breast carcinomas 
includes a number of variables such as tissue architecture, 
cellular differentiation, and size/presence of local or distant 
metastasis, which influence disease progression, risk assess-
ment, and prognosis. Other variables including estrogen re-
ceptor (ER), progesterone receptor (PR), and epidermal 
growth factor receptor-2 (HER2) expression vary widely 
among breast cancer patients and thus are routinely assessed 
as a component of standard care for determining the most 
effective treatment. At the molecular level, breast cancer has 
been found to exhibit extensive variability, with at least five 
tumor subtypes identified by patterns of gene expression [9, 
10]. In women with similar pathological characteristics, mo-
lecular heterogeneity of breast disease may cause clinical 
outcomes to vary widely even though patients receive identi-
cal treatments [11].  
  The extensive molecular and pathological diversity ob-
served in breast cancer patients suggests that breast cancer is 
not a homogeneous disease that can be effectively managed 
by a “standard of care” approach. Breast cancer may be more 
appropriately defined as a myriad of diseases characterized 
by variability in developmental pathways, propensity to me-
tastasize, and response to treatment that can only be success-
fully treated by regimens targeted to individual patients. Per-
sonalized medicine provides care and treatment based on 
fixed and modifiable risk factors unique to each patient, as 
well as pathological and molecular characteristics that make 
each breast carcinoma unique. In this review, we critically 
examine the role of inherited and somatic genomic variation 
in breast cancer, outlining the predictive utility of suscepti-
bility variants, extent and potential information content of 
cancer genomics, and the promise of personalized medicine 
and personalized oncology.  Breast Cancer and Personal Genomics  Current Genomics, 2010, Vol. 11, No. 3    147 
HEREDITARY BREAST CANCER 
Identification of Susceptibility Genes 
  The idea that breast cancer has a familial or inherited 
component was proposed as early as 1757 when Le Dran 
described a 19-year old woman with breast cancer whose 
grandmother and maternal uncle died of breast cancer [12]. 
In 1866, Broca characterized a family with ten women across 
four generations who were affected with breast cancer, and 
provided sufficient data to create a family pedigree that 
clearly showed the heritable nature of the disease [13]. More 
recently, twin studies and segregation/risk analysis have pro-
vided additional evidence that the development of breast 
cancer has a genetic component [14-17].  
  Identification of genes associated with the development 
of breast cancer is complicated by the co-occurrence of spo-
radic and heritable breast cancer within families. Because 
breast cancer affects one in eight women, approximately 
11% of families will contain more than one female with 
breast cancer [18], but it may be challenging to distinguish 
disease attributable to an inherited cancer susceptibility gene 
from chance clustering of sporadic breast cancer cases within 
a family. To identify breast cancer susceptibility genes, large 
extended families meeting stringent criteria for defining heri-
table breast cancer were needed. Using this approach, 23 
extended Caucasian families containing 146 individuals with 
breast cancer including early onset cases, bilateral disease, 
and/or male breast cancer were assembled. Forty percent of 
these families showed strong linkage to a marker on chromo-
some 17q21 [19]. In 1994, a novel gene with a zinc-finger 
domain and wide tissue expression, including breast and 
ovary, was identified as the breast cancer 1 gene (BRCA1) 
[20].  
  Despite the strong contribution of BRCA1 to hereditary 
breast and ovarian cancer, mutations in BRCA1 do not ac-
count for all cases of inherited breast cancer, implicating the 
existence of a second major susceptibility gene. Using tech-
niques similar to those used in the discovery of BRCA1, a 
novel gene on chromosome 13q12-q13 was identified as 
BRCA2 in 1995 [21, 22].  
  Following the identification of BRCA1 and BRCA2, 
screening tests were developed to identify mutation carriers 
and families at risk for hereditary breast and ovarian cancer. 
Screening is now recommended for women with breast can-
cer diagnosed at an early age, women with bilateral breast 
cancer, women with a family history of breast and ovarian 
cancer involving multiple family members (including 
males), and women of Ashkenazi Jewish ancestry [23]. Cur-
rently in the United States, Myriad Genetics 
(www.myriad.com) is the sole provider of BRACAnalysis
®, 
a direct sequencing approach to detect mutations in BRCA1 
and BRCA2.  
Patient Management 
  Clinical management of BRCA mutation carriers may 
include surgical intervention, chemoprevention, or increased 
surveillance. Although prophylactic mastectomy is the most 
effective intervention for BRCA1 and BRCA2 carriers, re-
ducing the risk of developing breast cancer by 90% [24], 
mastectomy is a highly invasive procedure with adverse 
physical and potentially devastating psychological effects. 
Thus, other non-surgical methods have been developed for 
detection and risk reduction [25]. As tamoxifen in BRCA 
mutation carriers with breast cancer has been shown to sig-
nificantly decrease the rate of contralateral disease [26], 
chemoprevention may be considered as part of an overall 
risk management program. In addition, magnetic resonance 
imaging (MRI) is more sensitive than mammography for 
detecting malignancy in BRCA carriers [27]. The Interna-
tional Consensus Conference on Breast Cancer Risk, Genet-
ics, and Risk Management recently advocated use of both 
mammography and MRI at alternating six-month intervals 
for screening BRCA mutation carriers [28].  
  BRCA status appears to confer a unique tumor phenotype 
that may contribute to poorer outcomes in patients with 
breast cancer. Primary breast tumors from BRCA1 mutation 
carriers have unique pathology, including high histological 
grade, atypical medullary histotype, high rates of cellular 
proliferation, pushing margins and infiltrating lymphocytes, 
and are frequently ER, PR, and HER2 negative (triple nega-
tive) [29]. These clinical attributes contribute to the “basal-
like” phenotype of BRCA1 breast carcinomas and may in-
fluence tumor behavior and aggressiveness. Some studies 
have observed lower survival in BRCA1 mutation carriers 
compared to non-carriers [30, 31], suggesting poorer out-
comes in patients with BRCA1 mutations; however, other 
studies have found no evidence of significant differences in 
long-term survival [32, 33].  
  The availability of genetic testing for BRCA mutations is 
potentially valuable in surgical decision making for newly 
diagnosed breast cancer patients, as approximately one-half 
of patients who are discovered to carry BRCA1/2 mutations 
are likely to choose bilateral mastectomy compared to only 
one-fourth of non-carriers [34]. At present, BRCA mutation 
status is not considered when making recommendations for 
systemic therapy because response to such therapies has not 
been shown to differ between carriers and non-carriers [28]. 
However, alterations in DNA repair caused by defects in 
BRCA1 and BRCA2 may enhance the sensitivity of BRCA-
positive tumors to platinum agents such as cisplatin and car-
boplatin, which cross-link DNA and interfere with replica-
tion [35]. Similarly, BRCA dysfunction sensitizes cells to 
poly(ADP-ribose) polymerase (PARP) inhibitors, leading to 
chromosomal instability, cell cycle arrest, and apoptosis in 
BRCA1 and BRCA2 deficient cells [36]. Clinical trials are 
currently underway to determine the efficacy of PARP in-
hibitors in treating BRCA deficient breast tumors, which 
may open new avenues for less toxic therapies that target 
particular DNA repair pathways in BRCA1 and BRCA2 mu-
tation carriers [37].  
Genomic Variability Among BRCA Carriers 
  Identification of BRCA1 and BRCA2 has improved 
clinical management of some individuals with hereditary 
breast and ovarian cancer, but personalized care is not yet 
available for mutation carriers. Important barriers to effec-
tive treatment include allelic heterogeneity, environmental 
effects, and genetic modifiers. Allelic heterogeneity, where 
different mutations in the BRCA1 and BRCA2 genes show 
variability in penetrance, has been associated with different 
risks for developing disease [38, 39]. Although many women 148    Current Genomics, 2010, Vol. 11, No. 3  Ellsworth et al. 
with BRCA mutations have a high probability of developing 
breast cancer, 15% of BRCA1-positive women and 20% of 
BRCA2-positive women will never develop breast cancer 
[40]. Likewise, environmental factors such as exercise and 
body weight, environmental exposures [41], contraceptive 
and hormone use, and reproductive history may influence 
tumor development in BRCA carriers [42]. Modifier genes 
are believed to contribute to variability in cancer risk, but the 
identification of genetic modifiers has been difficult. To 
date, only a single variant (-135G>C) in the recombination 
protein A (RECA or RAD51) gene has been confirmed as a 
genetic modifier in BRCA2 carriers [43]. The androgen re-
ceptor (AR), amplified in breast cancer 1 (AIB1), and aurora 
kinase (AURKA) genes have been implicated as genetic 
modifiers in BRCA carriers, but remain only candidates as 
positive results have yet to be replicated [44].  
  To hasten the identification of genetic modifier genes, the 
Consortium of Investigators of Modifiers of BRCA1 and 
BRCA2 (CIMBA) was established in 2005 as a “consortium 
of consortia”. With the collection of clinical data and genetic 
material from more than 15,000 BRCA1 and BRCA2 pa-
tients from around the world, genetic studies from CIMBA 
should have sufficient power to identify modifier genes [45]. 
Identification of genetic modifiers that influence risk of de-
veloping breast and/or ovarian cancer is needed to refine 
individual risk estimates and guide treatment options, includ-
ing the need for prophylactic mastectomy and/or oophorec-
tomy, in a personalized fashion.  
  Mutations in the BRCA1 and BRCA2 genes account for 
the majority of families with six or more cases of early-onset 
breast and/or ovarian cancer; however, many families with a 
high incidence of breast cancer have no detectable mutations 
in BRCA1 or BRCA2 [46], suggesting the existence of addi-
tional breast cancer susceptibility genes. Although genes 
associated with increased susceptibility have been identified, 
the majority of causative breast cancer genes remain un-
known [47] — see Fig. (1). Confounding factors such as (1) 
heterogeneous phenotypes attributable to several unidenti-
fied BRCA genes, each accounting for a small number of 
cancer cases; (2) genes influencing development of other 
types of cancer in addition to breast that may not be linked to 
breast cancer; and (3) weakly penetrant genes that are herita-
ble but resemble sporadic breast cancer in appearance [48] 
make the identification of high-risk breast cancer genes dif-
ficult, but critical to providing personalized and effective 
care to patients with hereditary and/or familial breast cancer. 
RISK ASSESSMENT FOR SPORADIC BREAST CAN-
CER 
Risk Estimation 
  Inherited mutations have been associated with 10-15% of 
all breast cancer cases; however, disease etiology in the ma-
jority of women appears to be sporadic, lacking a significant 
family history. Because sporadic breast cancer may be influ-
enced by a number of lifestyle and environmental factors as 
well as common low-risk variants in a number of genes, sev-
eral models have been developed in an attempt to quantify 
individualized breast cancer risk: 
•  The Gail model measures risk based on patient age, 
age at menarche, number of prior breast biopsies, age 
at first live birth, and number of first degree relatives 

















Fig. (1). Complexity and largely unknown molecular etiology of breast cancer. The majority of breast cancer cases (~70%) are considered 
sporadic in nature because individuals with disease do not have an extensive family history of breast cancer and molecular alterations con-
tributing to the disease have not been identified. Familial breast cancer (~30% of patients), often seen in families with a high incidence of 
breast cancer, has been associated with a number of high-, moderate-, and low-penetrance susceptibility genes.  Breast Cancer and Personal Genomics  Current Genomics, 2010, Vol. 11, No. 3    149 
•  The Claus model estimates risk based on the number 
of affected relatives and their respective age at diag-
nosis [50]. 
•  The BRCAPRO model calculates risk of developing 
breast cancer based on the probability of carrying a 
BRCA1 or BRCA2 mutation [51]. 
  These models have been widely used to predict risk and 
direct patient care, but each model has limitations because no 
model accounts for the spectrum of risk factors influencing 
breast cancer. For example, the Gail model considers only 
first-degree relatives without regard to age at diagnosis or 
presence of ovarian cancer, thus potentially underestimating 
genetic risk. The Claus and BRCAPRO models only con-
sider family history, potentially underestimating risk in 
women with other risk factors [52]. In addition, these models 
were developed 10-20 years ago when incidence of breast 
cancer in the general population was lower than it is today 
— use of lower baseline risk estimates may contribute to an 
underestimation of current risk [53]. More recent models, 
such as the Tyrer-Cuzick model, utilize family history, en-
dogenous estrogen exposure, and presence of benign disease 
to model breast cancer risk [54], but contributions from other 
factors such as mammographic breast density, weight gain, 
steroid hormone levels, and susceptibility genes have not 
been incorporated [55].  
  The discovery of the BRCA1 and BRCA2 genes ad-
vanced risk assessment in families affected by hereditary 
breast and ovarian cancer, but identification of molecular 
markers associated with increased breast cancer risk in pa-
tients without a family history of breast cancer has remained 
far more challenging. Without a strong family history, link-
age approaches involving large pedigrees such as those used 
to identify BRCA1 and BRCA2 are not applicable. Sporadic 
breast cancer is not usually associated with other cancers 
such as ovarian or male breast cancer and unlike BRCA1-
positive carcinomas, which exhibit specific histological 
characteristics, sporadic breast cancer cases comprise a vast 
array of phenotypes. Early approaches to identify sporadic 
breast cancer susceptibility genes compared the frequency of 
DNA variants in genes from molecular pathways believed to 
be involved in breast cancer development between cases 
with disease and healthy matched controls. An association 
study using candidate genes recently identified caspase-8 
(CASP8) as a low-risk susceptibility gene where the major 
(H) allele of the D302H polymorphism had a protective ef-
fect on the development of breast cancer [56]. Despite suc-
cess in identifying CASP8, candidate gene approaches have 
not been widely successful in identifying additional breast 
cancer susceptibility genes [57].  
Whole-Genome Approaches 
  Candidate gene approaches are rapidly giving way to 
genome-wide association studies (GWAS), which evaluate a 
dense array of genetic markers representing common 
variation throughout the genome. Completion of the human 
genome sequence and subsequent identification of single 
nucleotide polymorphisms (SNPs) now permits millions of 
informative SNPs across the genome to be assayed 
simultaneously. GWAS are useful for mapping genes of 
interest to small, localized regions of the genome and for 
detecting the effects of common (>5% minor allele 
frequency) alleles on disease risk [58]. Moreover, GWAS are 
performed without a priori knowledge of the underlying 
genetic defect(s), which may be advantageous since many 
genes identified through whole genome approaches were not 
previously suspected to influence the disease under 
investigation [59].  
  Recent GWAS have identified a number of loci that 
appear to be associated with breast cancer susceptibility 
(Table 1). For example, the fibroblast growth factor receptor 
2 (FGFR2), mitogen-activated kinase kinase kinase 1 
(MAP3K1), lymphocyte-specific protein (LSP1), and 
trinucleotide repeat-containing 9 (TNRC9/LOC643714) 
genes, along with a 110 kb region of chromosome 8q24 have 
been associated with breast cancer in large studies involving 
thousands of subjects [60, 61]. Associations with other 
chromosomal regions — 2q35, 5p12, 6q22, and 16q12 — 
also have been reported [62-64]. Further analysis has shown 
that allelic variation at FGFR2, TNRC9, 8q24, 2q35, and 
5p12 is associated with physiological characteristics of 
breast tumors, such as ER status [62, 64, 65], and specific 
FGFR2, MAP3K1, and TNRC9 variants may interact with 
Table  1.  Low-Penetrance Variants that may Influence Sporadic Breast Cancer Identified through Genome-Wide Association 
Studies 
SNP Chromosome  Candidate  Genes MAF
a OR
b Reference 
rs889312 5q11  MAP3K1  0.28  1.13  [60] 
rs2180341 6q22  ECHDC1,  RNF146  0.27  1.41  [63] 
rs2981582 10q26  FGFR2  0.38  1.26  [60,  61] 
rs3803662 16q12  TNRC9,  LOC643714  0.25  1.20  [60,  62] 
rs3817198 11p15  LSP1  0.30  1.07  [60] 
rs10941679 5p12  MRPS30  0.25  1.19  [64] 
rs13281615 8q24    0.40  1.08  [60] 
rs13387042 2q35    0.50  1.21  [62] 
aMAF = minor allele frequency. 
bOR = odds ratio per allele. 150    Current Genomics, 2010, Vol. 11, No. 3  Ellsworth et al. 
BRCA1 and BRCA2 mutations to increase breast cancer risk 
[66].  
  Despite recent success in identifying genetic determi-
nants of breast cancer, susceptibility alleles identified 
through GWAS are believed to account for only ~5% of 
breast cancer risk [67]. If future studies are to be successful 
in identifying additional low-risk susceptibility alleles and 
low-frequency, highly-penetrant variants [68], interactions 
between genes and environmental exposures must be as-
sessed [69] and methods must be developed to evaluate 
mechanisms by which DNA variants in intronic or intergenic 
regions contribute to disease. As risk associated with suscep-
tibility alleles may vary between racial/ethnic populations 
due to differences in frequency, patterns of disequilibrium, 
and interactions with environmental factors [60, 62, 70], 
sufficiently powered genetic studies in women from various 
ethnic groups are needed to improve risk reduction strategies 
for all women.  
Direct-to-Consumer Testing 
  New susceptibility variants identified by GWAS have not 
yet been incorporated into genetic tests with beneficial clini-
cal utility for breast cancer patients. However, genetic analy-
sis and risk assessment are available commercially through 
direct-to-consumer (DTC) testing. A number of for-profit 
companies offer personal genetic information based on DTC 
tests — the largest and most recognized companies include 
23andMe (www.23andme.com), deCODEme (www.deco-
deme.com), Navigenics
® (www.navigenics.com), and 
Knome
®, Inc. (www.knome.com/home) (Table 2). For a fee 
of $99 to $99,500 consumers provide a blood, buccal, or 
saliva sample for targeted SNP analysis or whole-genome 
sequencing. Genetic information provided to the consumer 
varies greatly among companies, from trivial facts such as 
ear wax type to ancestry information to information on risk 
for disease [71, 72]. Although DTC tests epitomize “person-
alized genomics” by providing consumers with individual 
genotypes, critics note that the clinical utility of such tests is 
limited and often incongruent with marketing claims. Be-
cause information on family history and environmental ex-
posures is usually not accounted for, DTC risk estimates may 
not be sufficiently accurate to enable consumers to make 
appropriate medical decisions [73, 74].  
  The majority of genetic risk assessments developed thus 
far focus on DNA variants; however, a new RNA-based sig-
nature has been developed for non-invasive breast cancer 
screening using peripheral blood samples. Although based 
on a small number of cases (n=24) and controls (n=32), a 
subset of 37 genes in the assay correctly classified 82% of 
patients [75]. Despite a relatively high misclassification rate, 
DiaGenic (www.diagenic.no) has since developed this gene 
expression signature into a clinical screening tool, currently 
available only in India as BCtect
™ India.  
MOLECULAR CHARACTERIZATION OF BREAST 
TUMORS – PERSONALIZED PROGNOSTICS 
Pathological Characterization 
  Human breast carcinomas exhibit diverse pathological 
characteristics that are associated with different clinical out-
comes, and thus are routinely used to guide treatment op-
tions. Accordingly, an accurate definition of prognosis is 
dependent on the ability to detect and quantify differences in 
tumor attributes, such as rates of proliferation and propensity 
to metastasize. Routine tumor evaluation currently includes: 
(1) histopathological classification; (2) grade determination; 
and (3) quantification of tumor size, surgical margin status, 
and lymph node involvement. Histopathological characteri-
zation, based on microscopic cellular morphology, classifies 
breast carcinomas into common subtypes (ductal or lobular 
carcinoma), which tend to have similar prognoses [76], or 
less common forms such as mucinous, tubular, and papillary 
(favorable prognosis) [77] or inflammatory breast cancer 
(poor prognosis) [78]. Increasing tumor size has long been 
associated with poor prognosis [79], but improved mammo-
graphic detection of smaller tumors has decreased the prog-
nostic utility of tumor size [80]. Presence of positive surgical 
margins has been associated with local recurrence, but only 
27% of patients with extensively positive margins will have 
recurrent disease [81, 82]. Likewise, the Nottingham His-
tological Score, widely used for assessing histological grade, 
is clinically useful for stratifying patients into low risk (low-
grade disease, 95% five-year survival) and high risk (high-
grade disease, 50% five-year survival) groups [83, 84], but 
the reliability of breast tumor grade in predicting survival is 
hampered by subjectivity associated with its assessment [85]. 
Axillary lymph node status is the most reliable predictor of 
survival, differentiating women who are likely to have >90% 
five-year survival (patients with negative nodes) from those 
who are likely to have <70% survival (women with nodal 
metastasis) [86]. Although these clinical attributes are cur-
Table 2.  Leading Direct-to-Consumer Genetic Testing Companies 
Company Headquarters  Website  Cost  (USD) Genetic   
Counseling 
Breast Cancer Susceptibility  
Variants 
23andMe  Mountain View, CA  www.23andme.com  $399  No  2 SNPS 
deCODEme Reykjavik,  Iceland  www.decodeme.com  $985
a Yes  11  variants
b 
Knome Cambridge,  MA  www.knome.com  Custom
c Yes  DNA  sequence 
Navigenics Foster  City,  CA  www.navigenics.com  $999
d Yes  unknown 
aComplete scan. 
bFor women of European descent. 
cKnomeSELECT
™ is $24,500 for complete sequence of 20,000 genes; KnomeCOMPLETE
™ is $99,500 for complete genome sequence. 
dOption for ongoing subscription ($199 per year) for updates. Breast Cancer and Personal Genomics  Current Genomics, 2010, Vol. 11, No. 3    151 
rently the standard of care for breast cancer patients, many 
are imprecise in their ability to accurately predict outcomes.  
Immunohistochemistry 
  Molecular markers have the potential to provide addi-
tional prognostic information to supplement traditional 
pathological assessments for disease management in breast 
cancer patients. As mentioned above, traditional immunohis-
tochemistry (IHC) markers routinely used in the classifica-
tion of breast cancer include ER, PR, and HER2. Tumors 
positive for ER and PR expression frequently have low cel-
lular proliferation rates, tend to exhibit lower histological 
grade, and are associated with more favorable prognosis 
[87]. ER and PR expression also is useful for identifying 
patients who will likely benefit from hormonal therapy, as 
women with ER and PR negative breast cancer do not gain a 
survival benefit from anti-estrogen tamoxifen [88].  
  The HER2 gene is a member of the epidermal growth 
factor receptor family with tyrosine kinase activity and is 
amplified at the DNA level and/or over-expressed in 15-25% 
of breast cancers. Carcinomas with amplified/over-expressed 
HER2 exhibit high histological grade and usually have a 
poor prognosis [89, 90]. Some patients with positive HER2 
status (15-20%) are eligible to receive trastuzumab, a mono-
clonal antibody targeting HER2, in combination with stan-
dard chemotherapy [91].  
  Rigorous clinical studies have shown that evaluating ER, 
PR, and HER2 status provides additional prognostic infor-
mation beyond that normally achieved by histological as-
sessment alone. For example, breast carcinomas that are ER-
negative, PR-negative, and do not have HER2 over ex-
pressed (triple negative) are marked by aggressive behavior, 
but because women with triple-negative disease are not eli-
gible for tamoxifen or trastuzumab treatment, they usually 
have relatively low long-term survival [92]. Other markers 
such as nuclear antigen Ki67 are not routinely used to guide 
treatment selection, but hold great promise for monitoring 
the effectiveness of neoadjuvant chemotherapy and predict-
ing recurrence-free survival [93-95].  
  Individual estimates of outcome using clinical and patho-
logical characteristics of breast tumors, including age, 
menopausal status, co-morbid conditions, tumor size, num-
ber of positive lymph nodes, and ER status have been incor-
porated into a computer program, Adjuvant! Online 
(www.adjuvantonline.com/index.jsp), which is available 
over the Internet as a decision aid for patients and their phy-
sicians [96]. The program estimates the efficacy of endocrine 
therapy and chemotherapy as well as overall and disease-free 
survival in a user-friendly format that effectively brings pa-
tients into the decision-making process regarding personal-
ized treatments.  
  Although IHC analysis of ER, PR, and HER2 is widely 
used in the pathological evaluation of breast tumors, addi-
tional molecular signatures involving multiple genes and/or 
proteins are desperately needed to more accurately classify 
tumors and guide treatment selection. Recently, a multi-gene 
IHC-based test known as MammoStrat
® (Applied Genomics, 
Huntsville, AL; www.applied-genomics.com/mammostrat. 
html) was developed to classify breast cancer patients into 
low-, moderate-, or high-risk categories for disease recur-
rence [97] (Table 3). MammoStrat
® uses conventional paraf-
fin-embedded tissue to assay five markers by IHC: tumor 
protein p53 (TP53) — known to play a central role in cell 
cycle regulation; Hpa II tiny fragments locus 9C (HTF9C) 
— involved in DNA replication and cell cycle control; carci-
noembryonic antigen-related cell adhesion molecule 5 
(CEACAM5) — aberrantly expressed in some cancers; 
nmyc downstream-regulated gene 1 (NDRG1) — may func-
tion as a signaling protein in growth arrest and cellular dif-
ferentiation; and solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5 (SLC7A5) — mediates 
amino acid transport. The MammosStrat
® test may have util-
ity for predicting patient outcomes, but currently requires 
five separate slides (one slide per antibody), which has the 
potential to show variability in staining intensity and scoring 
between patients.  
Gene Expression Signatures and Tumor Classification 
  With the sequencing of the human genome and identifi-
cation of many human genes, whole-genome approaches 
using array-based methods have been developed to evaluate 
expression levels for thousands of genes in a single experi-
Table 3.   Selected Molecular Diagnostic Tests for Breast Cancer 
Test Company  Assay  Type
a Number  of  Genes/Proteins  Classification  Reference 
Breast Bioclassifier
™  University Ge-
nomics 








®  Applied Genom-
ics 
IHC 5 Prognostic  [97] 
MapQuant DX
™ Ipsogen  Microarray  97  Tumor  grade  [103,  104] 
Oncotype DX
™ Genomic  Health  qRT-PCR  21  Prognostic  
Therapeutic guidance 
[108, 109] 
Rotterdam signature  Veridex  Microarray  76  Prognostic  [107] 
aqRT-PCR = quantitative real-time PCR; IHC = immunohistochemistry. 152    Current Genomics, 2010, Vol. 11, No. 3  Ellsworth et al. 
ment. Initial studies of human breast carcinomas identified 
several distinct subtypes of breast cancer using large-scale 
gene expression profiling: (1) ER positive (luminal-like), 
characterized by high expression of many genes expressed in 
breast luminal cells; (2) basal-like; (3) HER2 positive; and 
(4) normal-like [9]. Further experiments subdivided the lu-
minal (ER positive) tumors into luminal A and luminal B 
subtypes, and found that these five subtypes are useful in 
predicting relapse-free and overall survival, with the HER2 
positive and basal-like subtypes having the shortest survival 
times [10].  
  To improve the clinical utility of molecular signatures for 
predicting outcomes in women with breast cancer, a new 
gene signature encompassing a larger number of genes has 
been identified. The Single Sample Predictor (SSP) signature 
is reported to identify the original five intrinsic subtypes, 
plus a new “IFN-regulated” subtype, characterized by high 
expression of interferon-regulated genes [98]. Likewise, the 
Breast Bioclassifier
™ (University Genomics, Saint Louis, 
MO) is a commercial assay for classifying breast carcinomas 
by subtype. Expression levels for 55 genes provide subtype 
information and a continuous risk score to guide treatment 
options (www.bioclassifier.com/).  
  As gene expression signatures for classifying breast tu-
mors likely reflect underlying biological characteristics of 
disease, a number of gene expression signatures focusing on 
specific molecular pathways have been developed. For ex-
ample, tumorigenesis and wound healing share many similar 
physiological and molecular processes, including recruitment 
of inflammatory cells, stimulation of fibroblast and epithelial 
cell proliferation, cell migration, and angiogenesis. A 
“wound response” gene expression signature has been asso-
ciated with metastatic progression and mortality in breast 
cancer patients [99], and may improve risk stratification in-
dependently of established clinicopathological risk factors 
[100]. If the wound response signature proves to be effective 
in identifying patients at high-risk of recurrence after breast 
conserving therapy, it may be useful as a diagnostic tool to 
identify patients who should be offered more aggressive 
treatments, such as increased radiation, or who should con-
sider mastectomy rather than breast conserving therapy 
[101]. Likewise, breast carcinomas showing high levels of 
expression for hypoxia-related genes tend to exhibit p53 mu-
tations, negative ER status, and high histological grade, and 
have been associated with lower overall and disease-free 
survival [102].  
  Gene expression profiles are increasingly being used as 
molecular tools to complement pathological evaluation and 
guide treatment options. To overcome inherent subjectivity 
in histological grading of breast tumors, the Gene expression 
Grade Index (GGI) was developed to summarize the similar-
ity between gene expression profiles and tumor grade. The 
score attempts to classify low-grade and high-grade tumors, 
and to subdivide intermediate-grade tumors into low-grade, 
high-grade, or mixed-grade groups [103]. Further refinement 
of the gene expression grade index led to the MapQuant 
DX
™ Genomic Grade assay (Ipsogen, Marseille, France; 
www.ipsogen.com/), marketed as the first microarray-based 
diagnostic test to measure tumor grade [104]. With the re-
ported ability to classify ~80% of intermediate-grade breast 
tumors as either low-grade or high-grade, the MapQuant 
DX
™ Genomic Grade assay may be useful in guiding treat-
ment options, possibly sparing patients with low-grade 
(grade 1 or grade 1-like) tumors unnecessary treatments, 
while identifying those patients who would most likely bene-
fit from chemotherapy.  
Gene Expression Signatures and Disease Risk 
  Molecular profiles are now being used more frequently 
as clinical tools to determine treatment for certain groups of 
patients by categorizing them into low-risk and high-risk 
groups. The MammaPrint
™ assay (Agendia, Amsterdam, The 
Netherlands; www.agendia.com) is a 70-gene signature de-
veloped using tumor tissue from young women (<55 years of 
age) with node-negative disease, who either developed dis-
tant metastasis or remained disease-free after five-years 
[105]. Overall 10-year survival for the “poor-prognosis” sig-
nature is ~55%, while 10-year survival in women with the 
“good-prognosis” signature is 95%. The probability of being 
free from distant metastasis after 10 years is 51% for the 
poor prognosis and 85% for the good prognosis profile 
[106]. A second group of researchers subsequently devel-
oped a 76-gene profile (Rotterdam signature) that could 
identify breast cancer patients at high risk for distant recur-
rence. The signature could identify patients who developed 
distant metastases within five years when traditional prog-
nostic factors were considered (hazard ratio 5.55, 95% CI 
2.46–12.5) and could predict metastasis in both premeno-
pausal and postmenopausal patients [107].  
  The gene expression signatures outlined above were re-
fined from global expression profiling experiments involving 
thousands of genes and flash-frozen tumor specimens. An 
alternative approach relied on an extensive literature search 
to identify candidate genes (n=250) believed to be involved 
in disease development based on known function. Gene ex-
pression levels were assayed in 447 patients with ER-
positive, node-negative breast cancer to identify a small sub-
set of 16 genes (plus five reference genes) amenable to 
analysis by real-time-PCR (RT-PCR) on RNA isolated from 
formalin-fixed, paraffin-embedded (FFPE) specimens. The 
resulting 21-gene signature, known as Oncotype DX
® (Ge-
nomic Health, Redwood, CA; www.genomichealth.com/) 
provides a probability of recurrence score for women with 
early stage (Stage I or II), ER-positive, node-negative breast 
cancer, and categorizes patients as low-, intermediate-, or 
high-risk. In validation studies using patients from the Na-
tional Surgical Adjuvant Breast and Bowel Project (NSABP) 
clinical trial B-14 who received tamoxifen, the probability of 
distant recurrence at 10 years for the three risk categories 
was: low-risk — 6.8% (95% CI 4.0-9.6); intermediate-risk 
— 14.3% (95% CI 8.3-20.3); and high-risk — 30.5% (95% 
CI 23.6-37.4). Recurrence scores also correlated significantly 
with relapse-free interval and overall survival [108]. In a 
subsequent study, Oncotype DX
™ was used to assess the 
benefit of adjuvant chemotherapy in ER-positive, node-
negative patients. Because the highest benefit was observed 
in patients with high-risk scores, while women with low-risk 
recurrence scores did not benefit from chemotherapy [109], 
Oncotype DX
™ may be useful in guiding treatment options 
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  Clinical trials of the MammaPrint
™ and Oncotype DX
™ 
assays are currently in progress. In the Microarray In Node-
negative Disease may Avoid ChemoTherapy (MINDACT) 
trial, 6,000 node-negative women will be assigned to treat-
ment groups based on risk stratification by traditional clini-
cal-pathological factors (ADJUVANT! Online) and the 
MammaPrint
™ molecular signature [110]. Patients classified 
as low risk by both methods will not receive chemotherapy, 
while those considered high risk for relapse by both methods 
will be given the opportunity to receive adjuvant chemother-
apy. Patients of primary interest, those with discordant re-
sults, will be randomized to treatment based on either Adju-
vant! Online or MammaPrint
™ to determine which test is 
more effective in defining treatment in node-negative pa-
tients. The Trial Assigning Individualized Options for 
Treatment (TAILORx) is examining whether hormone re-
ceptor-positive patients with an intermediate Oncotype DX
™ 
risk recurrence score benefit from chemotherapy. The trial is 
recruiting 10,000 hormone-receptor-positive patients with 
HER2-negative and lymph-node-negative disease. Treatment 
will be based on the risk recurrence score as follows: <10 — 
hormone therapy alone; >26 — hormone and chemotherapy; 
intermediate scores — randomization to either hormone 
therapy alone or to hormone therapy and chemotherapy. The 
goal is to integrate Oncotype DX
™ into the clinical decision-
making process and refine the utility of the assay in clinical 
practice [111].  
  Molecular signatures have improved the ability to predict 
outcome and identify breast cancer patients who would most 
likely benefit from systemic therapy, thus providing an addi-
tional layer of personalized medicine. However, no current 
molecular signature is 100% accurate, and 5-10% of patients 
now classified as low-risk are likely to relapse. Furthermore, 
current classification systems were developed to predict only 
short-term (<5 years) outcomes; thus there is a need to de-
velop signatures that identify patients with protracted disease 
progression who may benefit from prolonged therapy [112]. 
Although outcome prediction tends to be similar between 
gene-expression signatures, overlap among genes comprising 
the signatures is relatively low, suggesting that these profiles 
assess common biological pathways, but have not identified 
the actual genes driving tumor behavior and outcome [113]. 
Finally, some multigene predictor assays are being adopted 
and marketed before they have been properly validated and 
proven to be clinically informative, thus the degree to which 
expression-based tests will alter the course of patient treat-
ment remains unclear [114, 115].  
PHARMACOGENOMICS OF BREAST CANCER 
  Pharmacogenomics in breast cancer evaluates the effect 
of inherited genomic variation on patient response or 
resistance to treatment. Genetic variability is commonly 
measured at the DNA level in the form of chromosomal 
alterations or DNA sequence variants (Table 4). Conversely, 
somatic genomic changes (DNA variants and gene 
expression profiles) in breast tumors can influence rates of 
apoptosis, cell proliferation, and DNA damage repair, which 
may have direct effects on response to treatment and 
survival. To be most effective, personalized medicine must 
incorporate information from innate genetic variation as well 
as somatic mutations in diseased tissue [116].  
Endocrine Therapy  
  Estrogens play an important role in the etiology of breast 
cancer by stimulating growth and proliferation of ductal 
Table 4.  Selected Genetic Polymorphisms Affecting Response to Therapy in Breast Cancer Patients 
Treatment  Gene  Variant  Functional Change  Response to Treatment  Reference 
Chemotherapy 
Doxorubicin  CBR3  11G>A  Decreased enzyme activity  Hematological toxicity  [142] 
Anthracyclines MnSOD  Ala
16  Higher levels of reactive oxygen spe-
cies 
Decreased mortality  [143] 
 MPO  —463GG  Higher levels of reactive oxygen spe-
cies 
Decreased mortality  [143] 
  GSTP1  313A>G  Altered drug transport  Hematological toxicity  [150] 
  MTHFR  1298A>C  Altered drug metabolism  Non-hematological toxicity  [150] 
Endocrine therapy 




Poor clinical outcome  [120, 121] 
Aromatase inhibitors  CYP19A1  Cys
264, Thr
364  Decreased enzyme activity  Reduced benefit  [128] 
Radiotherapy 
  TP53  Arg72Pro, PIN3  Decreased apoptosis  Risk of telangiectasia  [149] 
Targeted therapy 
Trastuzumab  HER2  Heterodimer  Prevents disruption by trastuzumab   Poor response to treatment  [132] 154    Current Genomics, 2010, Vol. 11, No. 3  Ellsworth et al. 
epithelial cells in the breast, thus the status of the estrogen 
receptor in breast carcinomas provided one of the earliest 
avenues for personalized medicine. Fortunately, hormone-
receptor-positive tumors usually are responsive to agents 
such as Tamoxifen that block the function of estrogen. 
Tamoxifen is a potent antagonist of the ER with inhibitory 
effects on tumor growth that has become the gold standard 
for endocrine treatment of estrogen-receptor-positive breast 
cancer in premenopausal and postmenopausal women [117]. 
Tamoxifen is associated with side effects such as blood clots, 
stroke, and increased risk of endometrial and uterine cancer, 
but five-year use of tamoxifen has been shown to reduce risk 
of cancer recurrence by ~50% [118]. For most patients, the 
benefit of using tamoxifen for hormone-receptor-positive 
disease outweighs the risk of serious side effects; however, a 
small subgroup of hormone-receptor-positive patients who 
carry specific variants in the cytochrome P450 2D6 
(CYP2D6) gene do not benefit from tamoxifen. The 
CYP2D6 gene is a key enzyme in the metabolism of 
tamoxifen to its active metabolite endoxifen. Several DNA 
variants in CYP2D6 result in poor metabolism of tamoxifen 
and lower levels of endoxifen [119]. Patients who carry 
reduced-function or nonfunctional CYP2D6 alleles have 
been found to derive inferior therapeutic benefit from 
tamoxifen and thus are at increased risk of breast cancer 
recurrence [120] or have significantly shorter disease-free 
survival than non-carriers [121]. Studies are underway to 
determine the utility of CYP2D6 genotyping for making 
clinical decisions about tamoxifen and the potential to 
optimize breast cancer therapy [122, 123].  
  Alternate forms of directed anti-estrogen therapies do 
exist for patients with hormone-receptor-positive breast 
cancer including aromatase inhibitors that block the 
production of estrogen, and compounds such as fulvestrant 
(Faslodex
®) that down-regulate and degrade the ER protein. 
Aromatase inhibitors such as anastrozole (Arimidex
®), 
letrozole (Femara
®), and exemestane (Aromasin
®) target 
cytochrome P450 19 (CYP19A1 or aromatase), an enzyme 
involved in estrogen synthesis in peripheral organs. 
Premenopausal women with functional ovaries do not 
receive aromatase inhibitor therapy because first and second 
generation aromatase inhibitors did not effectively suppress 
estrogen levels and because decreased estrogen levels in 
peripheral tissues could be counteracted by increased 
estrogen synthesis in the ovaries [124]. In postmenopausal 
women, aromatase inhibitors are well-tolerated and improve 
both disease-free and recurrence-free survival [125-127]. 
Similar to CYP2D6, the Cys
264 and Thr
364 variants in 
aromatase are associated with decreased activity and lower 
levels of immunoreactive protein, which may contribute to 
variation among patients in response to aromatase inhibitor 
therapy [128]. Although directed endocrine therapies provide 
treatments specific for patients with hormone-receptor-
positive breast cancer, factors such as menopausal status and 
innate genetic variability may alter the effectiveness of 
treatment.  
Treatment for HER2 Positive Breast Cancer 
  Therapies directed at the HER2 protein provide a second 
avenue of targeted treatment for some patients with breast 
cancer. Trastuzumab (Herceptin
®, Genentech, South San 
Francisco, CA; www.gene.com/) is a humanized monoclonal 
antibody that binds to the extracellular domain of the HER2 
protein, blocking tumor cell growth. Trastuzumab is the cur-
rent standard of care in adjuvant therapy for HER2-positive 
breast cancer, effective as a single agent or in combination 
with chemotherapeutics for the 20-25% of patients with 
HER2-positive cancer [129]. However, many patients with 
HER2-positive disease do not derive tangible benefit from 
trastuzumab. Given that the cost per patient for trastuzumab 
ranges from $20,000-$80,000 per year with the potential for 
significant adverse side effects [130], a more precise classifi-
cation of HER2-positive patients who will derive benefit 
from trastuzumab and improved understanding of how am-
plification and/or over-expression of HER2 contribute to 
aggressive tumor biology are critical to improving patient 
treatment.  
  The major oncogenic unit in HER2-positive breast cancer 
appears to be a heterodimer between the HER2 and epider-
mal growth factor receptor-3 (HER3) proteins, where HER3 
functions as a necessary dimerization partner for HER2 to 
achieve full oncogenic signaling potential [131]. Recent 
studies have shown that HER2/HER3 heterodimers promote 
cellular proliferation in both in vitro and in vivo models, 
suggesting that HER3 may be an important therapeutic target 
in HER2-positive patients [132]. Pertuzumab has been 
shown to bind to the dimerization arm of HER2, blocking 
HER2/HER3 heterodimerization and attenuating growth of 
solid tumors in model systems [133]. Thus, combining per-
tuzumab with trastuzumab may augment therapeutic benefit 
by blocking HER2/HER3 signaling. Monogram Biosciences 
(South San Francisco, CA; www.monogrambio.com/) has 
developed the commercially-available HERmark
™ test to 
measure total HER2 levels and HER2 homodimers in FFPE 
tissue and is developing a VeraTag
™ assay to quantify levels 
of HER2/HER3 heterodimers. These assays may allow pa-
tients with HER2-positive breast cancer to receive the most 
efficacious combination of new drugs targeting HER2.  
Chemotherapeutics 
  Chemotherapy involves use of chemical agents as part of 
a systemic treatment targeting proliferative cancer cells. Ad-
juvant chemotherapy is used to reduce risk of recurrence 
after primary therapy in women with localized breast cancer 
and to provide palliative care in patients with advanced (me-
tastatic) disease. In contrast, neoadjuvant chemotherapy is 
normally used to shrink moderate- to large-sized breast car-
cinomas prior to surgical resection, which permits use of less 
aggressive surgical options, including breast conservation, 
and may be useful in guiding longer-term treatment based on 
tumor response to specific drug combinations [134]. Obvi-
ously, the ability to predict which patients will benefit from 
adjuvant therapy and identify who will respond favorably to 
neoadjuvant regimens would provide an additional level of 
personalized care.  
Gene Expression and Chemotherapeutic Agents 
  Gene expression profiling has been used to study the bio-
logical responses of human breast carcinomas to optimize 
chemotherapeutic treatments. Cell lines derived from lumi-
nal and basal epithelium have been observed to respond dif-
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doxorubicin (DOX) and 5-fluorouracil (5FU). In culture, 
luminal cell lines show low levels of expression for genes 
regulating cellular proliferation and the cell cycle, while ba-
sal cell lines tend to repress genes involved in cellular differ-
entiation when exposed to DOX and 5FU [135]. Similarly, 
different molecular subtypes of breast cancer defined by 
gene expression profiling respond differently to preoperative 
chemotherapy, with basal-like and HER2-positive subtypes 
being more sensitive to paclitaxel and doxorubicin than lu-
minal and normal-like cancers [136]. Expression signatures 
also have been used to predict clinical response of breast 
cancer patients receiving either cyclophosphamide-
adriamycin or epirubicin-5FU as part of their adjuvant che-
motherapy regimen [137] and to distinguish primary breast 
tumors that are responsive or resistant to docetaxel chemo-
therapy [138]. These observations further highlight the vast 
amount of molecular variability among breast carcinomas 
and emphasize the need for additional molecular signatures 
to more effectively guide treatment.  
DNA Variation and Chemotherapeutic Agents 
  Clinical responses in breast cancer patients to commonly 
used chemotherapeutic agents vary considerably, from opti-
mum therapeutic response to partial (beneficial) response to 
severe adverse events. Variation at the DNA level in an in-
creasing number of genes is now known to affect the phar-
macokinetics and pharmacodynamics of many chemothera-
peutic drugs [139, 140], thus influencing toxicity and patient 
response. To improve the safety and efficacy of current 
treatments, therapies could be tailored to individual patients 
based on their genetic makeup [141]. For example, the car-
bonyl reductase 3 (CBR3) gene contributes to the reduction 
of DOX to doxorubicinol, a less potent metabolite, and the 
extent of metabolism is believed to be a source of variability 
in doxorubicin chemotherapy. The 11G>A variant 
(rs8133052) in CBR3 has been shown to influence tumor 
tissue expression of CBR3 and is associated with inter-
individual variability in clinical outcomes. Women with the 
11GG genotype experience greater leukocyte toxicity and are 
less likely to show a reduction in tumor size than women 
carrying 11AA [142].  
  A number of chemotherapeutics generate reactive oxygen 
species that function by damaging DNA and triggering the 
apoptotic cascade. Women carrying variants in genes associ-
ated with oxidative stress, such as manganese superoxide 
dismutase (MnSOD), catalase (CAT), and myeloperoxidase 
(MPO) that result in higher levels of reactive oxygen species, 
tend to have better overall survival than women with geno-
types associated with lower levels of reactive oxygen species 
when treated with chemotherapy [143]. Due to the large 
number of drug-metabolizing enzymes and drug transporters 
containing polymorphisms that affect chemotherapy-related 
toxicity and treatment outcomes in breast cancer patients, 
improved pharmacogenetic information is needed to identify 
individuals at risk for toxicity and poor response.  
Genomics in Clinical Practice 
  Recent developments in the clinical arena are indicative 
of the emerging importance of personal genomics in the pre-
vention, surveillance, and treatment of breast cancer. Profes-
sional organizations such as the American Society of Clini-
cal Oncology (ASCO) have issued recommendations on the 
use of molecular markers for guiding therapy and determin-
ing prognosis in breast cancer patients [144]:  
•  CA 15-3 and CA 27.29 (assays to detect circulating 
MUC-1 antigen in peripheral blood) — contributes to 
decisions regarding therapy for metastatic breast can-
cer in conjunction with diagnostic imaging, history, 
and physical examination 
•  Carcinoembryonic antigen (CEA) — contributes to 
decisions regarding therapy for metastatic breast can-
cer in conjunction with diagnostic imaging, history, 
and physical examination 
•  ER/PR — should be measured on every primary inva-
sive breast cancer to identify patients most likely to 
benefit from endocrine therapy 
•  HER2 — should be measured on every primary inva-
sive breast cancer at diagnosis or recurrence to guide 
trastuzumab therapy 
•  Urokinse plasminogen activator (uPA) and plasmino-
gen activator inhibitor 1 (PAI-1) — measured by 
ELISA on fresh or frozen tissue for determining 
prognosis in newly-diagnosed, node-negative breast 
cancer patients 
•  Oncotype DX
® — in newly-diagnosed patients with 
node-negative, ER-positive breast cancer, can be used 
to predict risk of recurrence in women treated with 
tamoxifen 
  Large cancer centers such as Massachusetts General 
Hospital (MGH) and Memorial Sloan-Kettering Cancer Cen-
ter (MSKCC) are now embracing the importance of genom-
ics in clinical practice, recently implementing policies to 
routinely assay a number of breast cancer-related genes — v-
akt murine thymoma viral oncogene homolog 1 (AKT1) and 
HER2 at MSKCC, phosphatase and tensin homolog (PTEN) 
and TP53 at MGH, and phosphatidylinositol 3-kinase, cata-
lytic, alpha (PIK3CA) at both institutions [145]. As genomic 
medicine becomes an integrated part of health care delivery, 
use of personalized genomics in the clinical treatment of 
breast cancer will increase.  
CONCLUSIONS 
  The era of personalized molecular medicine for breast 
cancer is on the horizon. Identification of strongly penetrant 
genes such as BRCA1 and BRCA2 has improved risk as-
sessment for women with hereditary forms of breast cancer, 
but sporadic breast cancer presents additional challenges due 
to the influence on disease risk of lifestyle and environ-
mental factors as well as common low-risk DNA variants. 
Substantial progress has been made in applying genomic 
discoveries to breast cancer treatment, as gene expression 
profiles are now being used to partition heterogeneous breast 
carcinomas into specific groups associated with different 
prognosis, pathological features, and developmental behav-
ior. Customized treatments based on genetic susceptibility of 
the patient and molecular characteristics of the tumor allow 
more effective treatments that minimize adverse drug reac-
tions. Yet despite these advances, personalized genomics in 
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have just begun to realize their full potential in clinical prac-
tice. Currently, the majority of genes contributing to sporadic 
breast cancer have not been identified. Whole-genome asso-
ciation studies have identified some DNA variants contribut-
ing to breast cancer risk that provide new insights into the 
pathophysiology of disease and may ultimately prove useful 
for developing targeted interventions [146], but many vari-
ants will never have clinical utility. Although molecular in-
formation may estimate risk and guide treatment in certain 
populations, expression profiles may not be applicable to 
other high-risk groups. To maximize the effectiveness of 
genomic data, other factors that influence breast cancer risk, 
such as the impact of environmental exposures, lifestyle fac-
tors, and personal behaviors must become integral compo-
nents of risk prediction models.  
  Recently proposed health-care reform legislation does 
not advocate personalized genomic medicine directly, but 
has the potential to profoundly affect genomics in medicine 
by adopting a shared decision making model that would in-
corporate patient preferences and values into their medical 
treatment plan. As educated patients become more knowl-
edgeable about personalized genomics, demand for molecu-
lar-based tests may increase dramatically. Expanded use of 
genetic information for tailoring treatments in breast cancer 
patients will present several challenges, such as managing 
the impact of genetic testing on healthcare delivery and cost 
[147]. In order to maximize the potential of personal genom-
ics in medicine, physicians must be fully prepared to deal 
with issues related to genomic tests, including the ability to 
critically evaluate and interpret genomic results [148] and 
issues such as cost-effectiveness, predictive limitations, and 
impact on quality of life must be considered.  
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